Benzinga - by Surbhi Jain, .
Uber Technologies Inc (NYSE:UBER) has been a standout performer, surging 117% over the past one year and maintaining dominance in both mobility and delivery. As we step into 2024, the question on investors’ minds is whether the ride-hailing giant’s stock can continue its impressive rally.
Technical indicators suggest waiting before you reserve your next ride. After a consistent bullish streak since late October 2023, Uber stock has been facing some resistance in December.
The on-balance volume (OBV) indicator is also treading downwards, indicating that trading volume on down days is outpacing trading volume on up days.
A falling OBV generally foreshadows lower prices.
Uber Solidified Its Position In The Industry
In 2023, Uber’s strong position in mobility and delivery, along with post-pandemic demand, contributed to its stock surge. The company’s expansion into various cities with taxi products has marked a full penetration into both traditional and modern ride-sharing markets, solidifying its position as a dominant player in the industry. It has also helped Uber outperform its closest ride-sharing peer, Lyft Inc (NASDAQ:LYFT).
Despite the positive outlook, concerns linger. Ongoing legal battles, safety issues, and uncertainties surrounding the business model pose risks to Uber’s operations. Though the company’s management has demonstrated adeptness in navigating labor laws, minimizing the potential financial impacts of these issues on the business.
Forward Valuations Spell Caution
Despite the significant YTD gains, some analysts are optimistic about further upside:
- Needham Reiterates Buy on Uber Technologies, Maintains $63 Price Target
- Goldman Sachs Maintains Buy on Uber Technologies, Raises Price Target to $78
Investors could thus, consider potential pullbacks, as entry points. While Uber’s financial success and expansion efforts indicate growth potential, the stock’s current valuation does warrant caution.
As the market navigates the uncertainties of 2024, the road ahead for Uber remains dynamic, presenting both opportunities and challenges for investors.
Now Read: Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.